Advances in non-surgical management of primary liver cancer

World Journal of Gastroenterology

Volumn 20, Issue 44, 2014, Pages 16630-16638

  Chen, Xiao ^a,b   Liu, Hai Peng ^a,b   Li, Mei ^a,b   Qiao, Liang ^c  

^a LANZHOU UNIVERSITY   (China)

^b Key Laboratory of Digestive System Tumors of Gansu Province   (China)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Ablation therapy; Biotherapy; Chemotherapy; Hepatocellular carcinoma; Hormonal therapy; Percutaneous ethanol injection; Percutaneous microwave coagulation therapy; Radiofrequency ablation; Radiotherapy; Transcatheter arterial chemoembolization

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; ERLOTINIB; INTERFERON; SEX HORMONE; SORAFENIB;

ABLATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CHEMOEMBOLIZATION; CRYOABLATION; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LIVER CANCER; META ANALYSIS (TOPIC); MICROWAVE RADIATION; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PERCUTANEOUS MICROWAVE COAGULATION THERAPY; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADVERSE EFFECTS; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; IMMUNOTHERAPY; LIVER NEOPLASMS; MORTALITY; PATHOLOGY; PATIENT SELECTION; RADIOTHERAPY; RISK FACTOR; TREATMENT OUTCOME; TRENDS;

ABLATION TECHNIQUES; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PATIENT SELECTION; RADIOTHERAPY; RISK FACTORS; TREATMENT OUTCOME;

EID: 84918794093     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i44.16630     Document Type: Article

References (70)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 [PMID: 15761078 DOI: 10.3322/canjclin.55.2.74]
2. Chen WQ, Zheng RS, Zeng HM, Zhang SW, Li N, Zou XN, He J. [Trend analysis and prediction of cancer incidence in China]. Zhonghua Yu Fang Yi Xue Zazhi 2012; 46: 581-586 [PMID: 22943910]
3. Centers for Disease Control and Prevention (CDC). Hepatocellular carcinoma - United States, 2001-2006. MMWR Morb Mortal Wkly Rep 2010; 59: 517-520 [PMID: 20448528]
4. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-928 [PMID: 2990661 DOI: 10.1002/1097-0142(19850815)56]
5. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751-755 [PMID: 9731568 DOI: 10.1002/hep.510280322]
6. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000; 31: 840-845 [PMID: 10733537 DOI:1053/ he.2000.5628]]
7. Llovet JM, Fuster J, Bruix J; Barcelona-Cl nic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10: S115-S120 [PMID: 14762851 DOI: 10.1002/lt.20034]
8. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338 [PMID: 10518312 DOI: 10.1055/s-2007-1007122]
9. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, Lau JT, Yu SC, Johnson PJ. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94:1760-1769 [PMID: 11920539 DOI: 10.1002/cncr.10384]
10. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]
11. Yin XY, Lu MD. Percutaneous ablation for small hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2009; 3: 121-130 [PMID: 19351283 DOI: 10.1586/egh.09.7]
12. Danila M, Sporea I, Sirii R, Popescu A. Percutaneous ethanol injection therapy in the treatment of hepatocarcinoma-results obtained from a series of 88 cases. J Gastrointestin Liver Dis 2009; 18: 317-322 [PMID: 19795026]
13. Kim SR, Imoto S, Nakajima T, Ando K, Mita K, Taniguchi M, Sasase N, Matsuoka T, Kudo M, Hayashi Y. Well-differentiated hepatocellular carcinoma smaller than 15 mm in diameter totally eradicated with percutaneous ethanol injection instead of radiofrequency ablation. Hepatol Int 2009; 3: 411-415 [PMID: 19669368 DOI: 10.1007/s12072-009-9128-z]
14. Khan KN, Yatsuhashi H, Yamasaki K, Yamasaki M, Inoue O, Koga M, Yano M. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection, J Hepatol 2000; 32: 269-278 [PMID: 10707867 DOI: 10.1016/S0168-8278]
15. Zhang YJ, Chen MS. The indications and application about radiofrequency ablation of liver cancer. J Hepatobiliary Surg 2010; 18: 9-10
16. Waki K, Aikata H, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Takahashi S, Toyota N, Ito K, Chayama K. Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up. J Gastroenterol Hepatol 2010; 25: 597-604 [PMID: 20074153 DOI: 10.1111/j.1440-1746.2009.06125.x]
17. Yang B, Zou J, Xia J, Ren Z, Gan Y, Wang Y, Zhang B, Ge N, Wang D, Chen Y, Chen R, Li L, Ye S, Wang X. Risk factors for recurrence of small hepatocellular carcinoma after long-term follow-up of percutaneous radiofrequency ablation. Eur J Radiol 2011; 79:196-200 [PMID: 20303686 DOI: 10.1016/ j.ejrad.2010.02.010]
18. Machi J, Uchida S, Sumida K, Limm WM, Hundahl SA, Oishi AJ, Furumoto NL, Oishi RH. Ultrasound-guided radio-frequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches. J Gastrointest Surg 2001; 5: 477-489 [PMID: 11985998 DOI: 10.1016/S1091-255X(01)80085-8]
19. Eisele RM, Denecke T, Glanemann M, Chopra SS. [Minimal-invasive microwave coagulation therapy for liver tumours: laparoscopic and percutaneous access]. Zentralbl Chir 2014; 139: 235-243 [PMID: 24241949 DOI: 10.1055/s-0033-1350931]
20. Tang Y, Zhou XD. Research progress of ultrasound interventional therapy for primary liver carcinoma. Disi Junyi Daxue Xuebao 2008; 29: 89-92
21. Kennedy JE. High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev Cancer 2005; 5: 321-327 [PMID: 15776004 DOI: 10.1038/nrc1591]
22. Zhang L, Zhu H, Jin C, Zhou K, Li K, Su H, Chen W, Bai J, Wang Z. High-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins. Eur Radiol 2009; 19: 437-445 [PMID: 18795303 DOI: 10.1007/s00330-008-1137-0]
23. Orsi F, Zhang L, Arnone P, Orgera G, Bonomo G, Vigna PD, Monfardini L, Zhou K, Chen W, Wang Z, Veronesi U. High-intensity focused ultrasound ablation: effective and safe therapy for solid tumors in difficult locations. A JR Am J Roentgenol 2010; 195: W245-W252 [PMID: 20729423 DOI: 10.2214 / AJR.09.3321]
24. Cormier JN, Thomas KT, Chari RS, Pinson CW. Management of hepatocellular carcinoma. J Gastrointest Surg 2006; 10: 761-780 [PMID: 16713550 DOI: 10.1016/j.gassur.2005.10.006]
25. Kerkar S, Carlin AM, Sohn RL, Steifes C, Tyburski J, Littrup P, Weaver D. Long-term follow up and prognostic factors for cryotherapy of malignant liver tumors. Surgery 2004; 136: 770-779 [PMID: 15467661 DOI: 10.1016/j.surg.2004.07.001]
26. Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S, Nabil M, Abdelkader A. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol 2009; 72: 505-516 [PMID: 18835117 DOI: 10.1016/j.ejrad.2008.08.007]
27. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y; Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-469 [PMID: 16890600 DOI: 10.1053/ j.gastro.2006.05.021]
28. Tezuka M, Hayashi K, Kubota K, Sekine S, Okada Y, Ina H, Irie T. Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma. Dig Dis Sci 2007; 52: 783-788 [PMID: 17268830 DOI: 10.1007/s10620-006-9537-y]
29. Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vase Interv Radiol 2005; 16: 1653-1659 [PMID: 16371532 DOI: 10.1097/01.RVI.0000182185.47500.7A]
30. Maluccio MA, Covey AM, Porat LB, Schubert J, Brody LA, Sofocleous CT, Getrajdman GI, Jarnagin W, Dematteo R, Blumgart LH, Fong Y, Brown KT. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vase Interv Radiol 2008; 19: 862-869 [PMID: 18503900 DOI: 10.1016/j.jvir.2008.02.013]
31. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50 [PMID: 15508101 DOI: 10.1053/ j.gastro.2004.09.014]
32. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver
33. cancer. Semin Liver Dis 1999; 19: 271-285 [PMID: 10518307 DOI: 10.1055/ s-2007-1007117]
34. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]
35. Zeng ZC, Jiang GL, Wang GM, Tang ZY, Curran WJ, Iliakis G. DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma hepG2 cell line. World J Gastroenterol 2002; 8: 797-803 [PMID: 12378618]
36. Kim TH, Kim DY, Park JW, Kim YI, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK, Kim CM. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 2006; 29: 568-575 [PMID: 17148993 DOI: 10.1097/01. coc.0000239147.60196.11]
37. Dawson LA, McGinn CJ, Normolle D, Ten Haken RK, Walker S, Ensminger W, Lawrence TS. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000; 18: 2210-2218 [PMID: 10829040]
38. Meng MB, Cui YL, Lu Y, She B, Chen Y, Guan YS, Zhang RM. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 2009; 92: 184-194 [PMID: 19042048 DOI: 10.1016/ j.radonc.2008.11.002]
39. You CR, Jang JW, Kang SH, Bae SH, Choi JY, Yoon SK, Choi IB, Lee DH, Chun HJ, Choi BG. [Efficacy of transarterial chemolipiodolization with or without 3-dimensional conformal radiotherapy for huge HCC with portal vein tumor thrombosis]. Korean J Hepatol 2007; 13: 378-386 [PMID: 17898554 DOI: 10.3350/kjhep.2007.13.3.378]
40. Kim DY, Park W, Lim DH, Lee JH, Yoo BC, Paik SW, Kho KC, Kim TH, Ahn YC, Huh SJ. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005; 103: 2419-2426 [PMID: 15822130 DOI: 10.1002/ cncr.21043]
41. Nakagawa K, Yamashita H, Shiraishi K, Nakamura N, Tago M, Igaki H, Hosoi Y, Shiina S, Omata M, Makuuchi M, Ohtomo K. Radiation therapy for portal venous invasion by hepatocellular carcinoma. World J Gastroenterol 2005; 11: 7237-7241 [PMID: 16437621]
42. Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Coin KA, Van Buskirk M, Roberts CA, Coin JE. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127: S194-S205 [PMID: 15508085 DOI: 10.1053/ j.gastro.2004.09.034]
43. Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J, Hendler AL, Coin JE. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-micro-spheres. J Nucl Med 2000; 41:1673-1681 [PMID: 11037997]
44. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007; 26: 2166-2176 [PMID: 17401425 DOI: 10.1038/sj.onc.1210279]
45. Watanuki A, Ohwada S, Fukusato T, Makita F, Yamada T, Kikuchi A, Morishita Y. Prognostic significance of DNA topoisomerase Ilalpha expression in human hepatocellular carcinoma. Anticancer Res 2002; 22: 1113-1119 [PMID: 12168909]
46. Ng IO, Liu CL, Fan ST, Ng M. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am J Clin Pathol 2000; 113: 355-363 [PMID: 10705815 DOI: 10.1309/AC1M-4TY4-U0TN-EN7T]
47. Palmer DH, Hussain SA, Johnson PJ. Systemic therapies for hepatocellular carcinoma. Expert Opin Investig Drugs 2004; 13: 1555-1568 [PMID: 15566313 DOI: 10.1517/13543784.13.12.1555]
48. Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin, J Clin Oncol 2007; 25: 3069-3075 [PMID: 17634485 DOI: 10.1200/JCO.2006.08.4046]
49. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006; 11: 790-800 [PMID: 16880238 DOI: 10.1634/theoncolo-gist.11-7-790]
50. O'Reilly EM, Stuart KE, Sanz-Altamira PM, Schwartz GK, Steger CM, Raeburn L, Kemeny NE, Kelsen DP, Saltz LB. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 2001; 91: 101-105 [PMID: 11148565 DOI: 10.1002/1097-0142(20010101)91]
51. Halm U, Etzrodt G, Schiefke I, Schmidt F, Witzigmann H, Mössner J, Berr F. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 2000; 11: 113-114 [PMID: 10690399 DOI: 10.1023/ A:1008386822906]
52. Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 2005; 103: 756-762 [PMID: 15637692 DOI:1002/ cncr.20841]
53. Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Joh J, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 2004; 54: 385-390 [PMID: 15248028 DOI: 10.1007/s00280-004-0837-7]
54. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, Corbett TJ, Chow AW, Lin HJ. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17: 389-394 [PMID: 8383088 DOI: 10.1002/hep.1840170307]
55. Tungpradabkul S, Sandee D, Puthong S, Laohathai K. Construction of scFv derived from a tumor-associated monoclonal antibody having tumoricidal activity on human hepatocellular carcinoma. Mol Immunol 2005; 42: 713-719 [PMID: 15781115 DOI: 10.1016/j.molimm.2004.09.023]
56. Bertelli R, Neri F, Tsivian M, Ruhrman N, Cavallari G, Beltempo P, Puviani L, DeVinci C, Pizza G, Nardo B. Endolymphatic immunotherapy in inoperable hepatocellular carcinoma. Transplant Proc 2008; 40:1913-1915 [PMID: 18675087 DOI: 10.1016/j.transproceed.2008.05.049]
57. Peng BG, Liang LJ, He Q, Kuang M, Lia JM, Lu MD, Huang JF. Tumor vaccine against recurrence of hepatocellular carcinoma. World J Gastroenterol 2005; 11: 700-704 [PMID: 15655825]
58. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27: 55-76 [PMID: 17295177 DOI: 10.1055/S-2006-960171]
59. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327 [PMID: 18821591 DOI: 10.1002/hep.22506]
60. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJ-Moa0708857]
61. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 2008; 8: 592-603 [PMID: 18650835 DOI: 10.1038/nrc2442]
62. van Malenstein H, Dekervel J, Verslype C, Van Cutsem E, Windmolders P, Nevens F, van Pelt J. Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett 2013; 329: 74-83 [PMID: 23111106 DOI: 10.1016/j.canlet.2012.10.021]
63. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 2006; 98: 1755-1757 [PMID: 17179471 DOI: 10.1093/jnci/ djj505]
64. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23: 6657-6663 [PMID: 16170173 DOI: 10.1200/JC0.2005.14.696]
65. Huether A, Hopfner M, Baradari V, Schuppan D, Schembl H. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 2005; 70: 1568-1578 [PMID: 16226226 DOI: 10.1016/j.bcp.2005.09.007]
66. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009; 64: 777-783 [PMID: 19169683 DOI: 10.1007/s00280-009-0927-7]
67. Boonyaratanakornkit V, Edwards DP. Receptor mechanisms mediating non-genomic actions of sex steroids. Semin Reprod Med 2007; 25:139-153 [PMID: 17447204 DOI: 10.1055/ s-2007-973427]
68. Shimizu I, Ito S. Protection of estrogens against the progression of chronic liver disease. Hepatol Res 2007; 37: 239-247 [PMID: 17397511 DOI: 10.1111/j.1872-034X.2007.00032.x]
69. Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Soo KG; Asian-Pacific Hepatocellular Carcinoma Trials Group. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002; 36: 1221-1226 [PMID: 12395333 DOI: 10.1053/jhep.2002.36824]
70. Nowak A, Findlay M, Culjak G, Stockier M. Tamoxifen for hepatocellular carcinoma. Cochrane Database Syst Rev 2004; (3): CD001024 [PMID: 15266436]